Routine heparin for patients with cancer? One answer, more questions

New England Journal of Medicine

Volumn 366, Issue 7, 2012, Pages 661-662

  Akl, Elie A ^a,b   Schünemann, Holger J ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; SEMULOPARIN;

BLEEDING; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; LOW DRUG DOSE; PATIENT ATTITUDE; PRIORITY JOURNAL; RISK REDUCTION; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84857128698     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1113672     Document Type: Editorial

References (4)

1. Borsig L. Heparin as an inhibitor of cancer progression. Prog Mol Biol Transl Sci 2010;93:335-49.
2. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601-9.
3. Akl EA, Gunukula S, Barba M, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011;4:CD006652.
4. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29:2071-6.